Abstract:Epidemiological studies established an association between chronic inflammation and higher risk of cancer. Inhibition of proteolytic enzymes represents a potential treatment strategy for cancer and prevention of cancer metastasis. Cathepsin C (CatC) is a highly conserved lysosomal cysteine dipeptidyl aminopeptidase required for the activation of pro-inflammatory neutrophil serine proteases (NSPs, elastase, proteinase 3, cathepsin G and NSP-4). NSPs are locally released by activated neutrophils in response to pathogens and non-infectious danger signals. Activated neutrophils also release neutrophil extracellular traps (NETs) that are decorated with several neutrophil proteins, including NSPs. NSPs are not only NETs constituents but also play a role in NET formation and release. Although immune cells harbor large amounts of CatC, additional cell sources for this protease exists. Upregulation of CatC expression was observed in different tissues during carcinogenesis and correlated with metastasis and poor patient survival. Recent mechanistic studies indicated an important interaction of tumor-associated CatC, NSPs, and NETs in cancer development and metastasis and suggested CatC as a therapeutic target in a several cancer types. Cancer cell-derived CatC promotes neutrophil recruitment in the inflammatory tumor microenvironment. Because the clinical consequences of genetic CatC deficiency in humans resulting in the elimination of NSPs are mild, small molecule inhibitors of CatC are assumed as safe drugs to reduce the NSP burden. Brensocatib, a nitrile CatC inhibitor is currently tested in a phase 3 clinical trial as a novel anti-inflammatory therapy for patients with bronchiectasis. However, recently developed CatC inhibitors possibly have protective effects beyond inflammation. In this review, we describe the pathophysiological function of CatC and discuss molecular mechanisms substantiating pharmacological CatC inhibition as a potential strategy for cancer treatment.

A Multifunctional Protease Inhibitor To Regulate Endolysosomal Function

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Synthesis and biological evaluation of selective pepstatin based trifluoromethylated inhibitors of Cathepsin D

Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

Antibody–peptide conjugates for targeted inhibition of cysteine proteases

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin

Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors.

Advances in Cathepsin S Inhibition: Challenges and Breakthroughs in Drug Development

Endoprotease-mediated intracellular protein delivery using nanocapsules.

Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases)

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases

Targeted Lysosomal Degradation of Secreted and Cell Surface Proteins through the LRP-1 Pathway

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect

Competitive Inhibition of the Endoplasmic Reticulum Signal Peptidase by Non-cleavable Mutant Preprotein Cargos.

Cathepsin C inhibition as a potential treatment strategy in cancer

Recent Advances In The Discovery Of Novel Peptide Inhibitors Targeting 26s Proteasome

Structure-based computer-aided drug design to identify potential lead molecules for Asparaginyl Endopeptidase inhibitors

Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome.

Cathepsin B and L Inhibitors: a Patent Review (2010 - Present).

Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library